<DOC>
	<DOCNO>NCT01363739</DOCNO>
	<brief_summary>-1498C/T VEGF polymorphism , suggest recent retrospective analysis , seem role predict efficacy Bevacizumab plus FOLFIRI first-line treatment metastatic colorectal cancer patient . The present study aim prospectively evaluate predictive role polymorphism metastatic colorectal patient receive treatment .</brief_summary>
	<brief_title>Evaluation VEGF Polymorphism Predictive Factor Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma ; Measurable metastatic disease accord RECIST criterion ; Patients receive BV plus FOLFIRI firstline treatment ; Written inform consent ; Availability blood sample genetic analysis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>VEGF polymorphism Bevacizumab</keyword>
</DOC>